New insider activity at 10x Genomics ( (TXG) ) has taken place on February 27, 2025.
In recent transactions, CEO Serge Saxonov sold 5,092 shares of 10x Genomics stock, amounting to $56,317. Additionally, President and Chief Scientific Officer Benjamin J. Hindson sold 4,573 shares, totaling $50,577.
Recent Updates on TXG stock
In the last 24 hours, 10x Genomics has seen several price target adjustments from analysts, primarily due to financial risks and market challenges. Barclays and TD Cowen both lowered their price targets to $15, citing concerns about the company’s ability to maintain growth amidst revenue challenges and market uncertainties. The company’s recent earnings call highlighted a mixed outlook, with innovations in product development being overshadowed by a decline in overall revenue and uncertainties in NIH funding. Despite a 33% increase in spatial product revenue and improved gross margins, the company faced a 1% decline in total revenue for 2024 and significant drops in instrument revenue. Analysts are cautious about the company’s future growth prospects, given the complexity of data interpretation challenges faced by customers and potential impacts from NIH funding changes.
More about 10x Genomics
YTD Price Performance: -21.71%
Average Trading Volume: 2,222,380
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.36B